Research programme: mitochondrial disorders therapeutics - Mitobridge

Drug Profile

Research programme: mitochondrial disorders therapeutics - Mitobridge

Alternative Names: MTB-1; PPARδ modulators - Mitobridge

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Mitobridge
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mitochondrial disorders

Most Recent Events

  • 07 Dec 2016 Astellas plans to file an IND application with the US FDA for Mitochondrial disorders
  • 16 Sep 2015 Mitobridge and the Center for Mitochondrial and Epigenomic Medicine enter into a sponsored research agreement for Mitochondrial disorder therapeutics
  • 23 Feb 2015 Mitogene licenses patents and reagents related to peroxisome proliferator-activated receptor delta from Salk Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top